Reduction of AZGP1 predicts poor prognosis in esophageal squamous cell carcinoma patients in Northern China
Authors Tang H, Wu Y, Qin Y, Wang H, Wang L, Guan X, Luo S, Wang Q
Received 31 May 2016
Accepted for publication 8 November 2016
Published 20 December 2016 Volume 2017:10 Pages 85—94
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Lucy Goodman
Peer reviewer comments 3
Editor who approved publication: Dr Ingrid Espinoza
Hong Tang,1,* Yufeng Wu,1,* Yanru Qin,2 Haiying Wang,1 Lili Wang,1 Xinyuan Guan,3 Suxia Luo,1 Qiming Wang1
1Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 2Department of Clinical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 3Department of Clinical Oncology, The University of Hong Kong, Hong Kong, People’s Republic of China
*These authors contributed equally to this work
Background: As a key regulator in lipid mobilization, AZGP1 has been reported to play a significant role in various cancers. This study was carried out to investigate the role of AZGP1 in the development of esophageal squamous cell carcinoma (ESCC) patients in Northern China.
Materials and methods: Through the application of quantitative real-time polymerase chain reaction and immunohistochemical staining, AZGP1 expression in ESCC tissues from Northern China was examined.
Results: Decreased expression of AZGP1 was observed in ~60% ESCC patients. AZGP1 downregulation was significantly associated with lymph node metastasis (P=0.035), advanced clinical stage (P=0.018), poor prognosis for 5-year disease-specific survival (DSS; P<0.001), local recurrence-free survival (LRFS; P=0.016), and metastasis-free survival (MeFS; P=0.014). In addition, Cox multivariate analysis revealed that AZGP1 downregulation remained to be an independent prognosticator for shorter DSS (P=0.001), LRFS (P=0.011), and MeFS (P=0.004).
Conclusion: AZGP1 might be a candidate tumor suppressor and a potential novel prognostic biomarker for ESCC patients in Northern China.
Keywords: AZGP1, ESCC, prognosis, Northern China
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]